Skip to content
QuidelOrtho Corporation logo

QuidelOrtho Corporation

QDEL

QuidelOrtho is a global provider of in vitro diagnostics, specializing in immunoassay and molecular testing, clinical chemistry, and transfusion medicine.

Market cap
$1.15B-30.1%
Revenue$2.7B-3.9%
Net income-$1.2B-238%
Free cash flow-$236.6M-422%
EPS (diluted)-$17.80-235%
Trailing twelve months · change vs. prior year

Earnings

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$619.5M
EPS estimate-$0.04

Financials

Q1 2026

Income statement

See full
Revenue$619.8M-10.5%
Gross profit$263.8M-23.2%
Operating income-$31.8M-198%
Net income-$91.8M-623%
EPS (diluted)-$1.35-611%

Balance sheet

See full
Cash & equivalents$140.4M+10.4%
Total debt$3.1B+0.3%
Total equity$1.9B-38.2%
Total assets$5.6B-12.9%

Cash flow

See full
Operating cash flow-$33.0M-150%
CapEx$34.0M-39.5%
Free cash flow-$67.0M-813%

Valuation & ratios

Valuation

See full
Market cap$1.15B-30.1%
Enterprise value$4.11B-13.1%
P/S0.4×-0.2×

Profitability

See full
Gross margin45%-2.0pp
Operating margin-37%-46.2pp
Net margin-45.6%-75.7pp

Returns & leverage

See full
Return on equity-49.9%-70.8pp
Debt / equity1.7×+0.6×
Current ratio1.4×+0.2×

Segments

By segment

See full
North America$328.9M-19.1%
EMEA$92.5M+4.0%
JPAC$70.0M+2.8%
Latin America$64.9M+20.0%
China$63.5M-15.3%

Competitors

Profile

QuidelOrtho is a global provider of in vitro diagnostics, specializing in immunoassay and molecular testing, clinical chemistry, and transfusion medicine. The company delivers diagnostic solutions across the continuum of care, from high-throughput hospital laboratories to point-of-care settings and over-the-counter consumer use. Its core value proposition centers on providing rapid, accurate diagnostic results that improve clinical outcomes and operational efficiency for healthcare providers in over 140 countries.

Competitive position

A leading global provider of in vitro diagnostics with a dominant position in point-of-care rapid testing and a significant footprint in automated transfusion medicine.

GeographiesNorth America, EMEA, China, JPAC, Latin America
Customer segmentsHealthcare providers, Clinical laboratories, Blood centers, Direct-to-consumer
Business modelRazor-and-blade, Equipment sales, Consumables, Service and maintenance
SuppliersSpecialized chemical and biological reagent suppliers, Electronic component manufacturers, Plastic injection molding for consumables, Logistics and cold-chain providers
CustomersHospitals and health systems, Independent clinical laboratories, Retail pharmacies, Government health agencies, Blood donation organizations
Listed1981
Employees7.1K
CEOBrian J. Blaser
FilingsSEC EDGAR

Questions, answered.

What is QuidelOrtho Corporation's market cap?
QuidelOrtho Corporation (QDEL) has a market capitalization of $1.1B and trades on NASDAQ.
What is QuidelOrtho Corporation's revenue and profitability?
QuidelOrtho Corporation generated $2.7B in trailing twelve-month revenue with a net loss of $1.2B, representing a net margin of -45.6%. Gross margin stands at 45.0%, with free cash flow of -$236.6M. These figures are based on the Q2 2026 filing.
Who are QuidelOrtho Corporation's competitors?
QuidelOrtho Corporation's key competitors include Bio-Rad Laboratories, Danaher Corporation, Abbott Laboratories, and others. These companies compete in similar markets and product categories.
Who does QuidelOrtho Corporation partner with?
QuidelOrtho Corporation's notable partners include Aquant.
What subsidiaries does QuidelOrtho Corporation have?
QuidelOrtho Corporation's subsidiaries include Ortho Clinical Diagnostics.
Where is QuidelOrtho Corporation headquartered?
QuidelOrtho Corporation is headquartered in United States of America and employs approximately 7,100 people. It has been publicly traded since 1981.